…minutes after the infusion ends, it is useful in patients where beta-blockade is desirable but risky — impending heart failure, obstructive lung disease, uncertain haemodynamics.

…vessels — completely without alpha effect. The result is that heart rate rises while systemic vascular resistance and diastolic blood pressure fall, so the drug raises…

…Reduces mortality in heart failure with reduced ejection fraction — the effect is dose-dependent, and underdosing is more often than adverse effects the reason for…

…musculoskeletal and postoperative pain, but with the most unfavourable cardiovascular profile in the class — the increase in risk for myocardial infarction, stroke, and heart failure…

…benefit in heart failure (CHARM), and the first choice when an ACE inhibitor must be switched due to cough. The target dose in heart failure…

…reduced cardiovascular death and worsening heart failure with reduced ejection fraction, DELIVER showed equivalent benefit with preserved and mildly reduced EF, and DAPA-CKD demonstrated…

…Unlike verapamil and diltiazem, amlodipine has no clinically significant negative inotropic effect and can therefore be used in heart failure with reduced ejection fraction when…

…for depression and generalised anxiety disorder. What governs dosing is not efficacy but the heart: a dose-dependent QT prolongation was identified, and the maximum…

…reduces heart rate without affecting contractility, blood pressure, or conduction — it inhibits the funny current (If) that drives spontaneous depolarisation of the sinus node and…

…blockers, with documented mortality benefit in heart failure from CIBIS-II. Bioavailability is close to 90 % and elimination is equally shared between liver and kidney…

…reduced heart failure events regardless of ejection fraction in EMPEROR-Reduced and EMPEROR-Preserved, and slowed renal function decline down to eGFR 20 in EMPA…

Tambocor Class IC antiarrhythmic A potent sodium channel blocker with marked efficacy on atrial arrhythmias in structurally normal hearts. The CAST trial showed increased mortality…

…sätter först vid både depression och ångestsyndrom, och det bäst dokumenterade vid samtidig hjärt- och kärlsjukdom — svag CYP-hämning, ingen kliniskt relevant QT-förlängning i…

…fyra doser. Naproxen har den mest gynnsamma kardiovaskulära profilen bland NSAID och är därför förstahandsval när ett NSAID måste ges till patient med hjärt-kärlsjukdom.